Author Topic: (Abst.) Nasal foralumab shows promise in nonactive SPMS (CMSC annual meeting)  (Read 25 times)

0 Members and 0 Guests are viewing this topic.

Offline agate

  • Administrator
  • *****
  • Posts: 9542
  • MS diagnosed 1980
  • Location: Pacific Northwest

This abstract of a paper presented by researchers at Harvard University involves only one patient, but this statement in the abstract is worth noting:

There are no effective treatments for non-active secondary progressive MS (SPMS), which is mediated by compartmentalized CNS inflammation, including activated microglia.

From the recent CMSC conference (June 2, 2022)--"Nasal anti-CD3 monoclonal antibody (Foralumab) reduces PET microglial activation and blood inflammatory biomarkers in a patient with nonactive  secondary progressive MS":

From MedPage Today (July 8, 2022), a brief commentary by Lawrence Steinman, MD, of Stanford University, on this research. The video may not be available but the transcript of his remarks is--entitled "Nasal Anti-CD3 Monoclonal Antibody Shows Promise in Progressive MS":

« Last Edit: July 08, 2022, 09:17:34 am by agate »
MS Speaks--online for 17 years

SPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010. Glatopa (glatiramer acetate 40mg 3 times/week) since 12/16/20.


Related Topics

  Subject / Started by Replies Last post
2 Replies
Last post May 14, 2018, 08:47:09 pm
by agate
0 Replies
Last post September 15, 2020, 08:57:39 pm
by agate
0 Replies
Last post April 11, 2021, 08:59:30 pm
by agate
0 Replies
Last post November 15, 2021, 09:20:43 pm
by agate
0 Replies
Last post April 28, 2022, 08:43:27 pm
by agate